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Context: CD36 is a class B scavenger-receptor involved in the uptake of fatty acids in liver 
and adipose tissue. It is unknown whether plasma CD36 levels are related to liver fat content 
or adipose tissue in the general population.  
Methods: We measured plasma CD36 from 575 participants of the community-based 
PopGen-cohort who underwent magnetic resonance imaging (MRI) to quantify visceral 
(VAT) and subcutaneous (SAT) adipose tissue and liver signal intensity (LSI), a proxy for 
liver fat content. Non-alcoholic fatty liver diseas (NAFLD) was defined as LSI ≥3.0 in the 
absence of high alcohol intake. The relations betwen plasma CD36 and body mass index 
(BMI), VAT, SAT, LSI, and NAFLD were evaluated using multivariable-adjusted linear and 
logistic regression analysis.  
Results: Plasma CD36 concentrations were correlated with BMI (r=0.11; P=0.01), SAT 
(r=0.16; P<0.001), and VAT (r=0.15, P<0.001), but not with LSI (P=0.44). In multivariable-
adjusted regression models, mean BMI values rose across CD36-quartiles (Q1: 27.8 kg/m2; 
Q4: 28.9 kg/m2; P-trend=0.013). Similarly, VAT (Q1: 4.13 dm3; Q4: 4.71 dm3; P-
trend<0.001) and SAT (Q1: 7.61 dm3; Q4: 8.74 dm3; P-trend<0.001) rose across CD36 
quartiles. Plasma CD36 concentrations were unrelated to LSI (P-trend=0.36), and NAFLD 
(P-trend=0.64). Participants with NAFLD and elevated alanine aminotransferase (ALT), a 
marker for liver damage, had higher CD36 compared to NAFLD participants with normal 
ALT. 
Conclusions: Higher plasma concentrations of CD36 were associated with greater general 
and abdominal adiposity, but not with liver fat content or NAFLD in this community-based 
sample. However, plasma CD36 may reflect more severe liver damage in NAFLD. 
We provide evidence that plasma CD36 levels are associated with general and abdominal adiposity, 
but not with MRI-determined liver fat content, in a general population sample. . 
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INTRODUCTION  
 The global prevalence of obesity has tripled in the past two decades (1). In 2016, 
more than 650 million adults worldwide were obese, representing 13% of the total global 
population (1). Up to 90% of obese patients have non-alcoholic fatty liver disease (NAFLD) 
(2), which represents the most common chronic liver condition, characterized by liver fat 
accumulation (3). Both obesity and NAFLD are significant risk factors for increased 
morbidity and mortality, e.g. from type 2 diabetes, cardiovascular disease and cancer (4,5). 
Therefore, it is of scientific importance to deepen our understanding of the underlying 
etiology and look for effective targets for the prevention and treatment of obesity. 
 CD36 is a multifunctional glycosylated protein widely expressed in a variety of 
tissues (6). In metabolically active tissues such as liver and adipose tissue, CD36 functions as 
a lipid transporter that binds and uptakes long-chain fatty acids and thereby fosters fat 
accumulation in hepatocytes and adipocytes (6). In line with its biological function, CD36 
expression has been reported to be upregulated in hepatocytes of patients with fatty liver 
(7,8), and in adipose tissue of obese individuals (9). In addition, human genetic studies have 
identified several genetic variants in the CD36 gene to be associated with traits reflecting 
lipid metabolism and obesity (10-12).  
 Traditionally, the measurement of CD36 required fresh blood or tissue samples and 
was therefore not feasible in large-scale population studies. Recent research efforts enabled 
the assessment of plasma CD36 in stored plasma samples (13). In subsequent studies, plasma 
CD36 levels were correlated with CD36 expression (14) and with body mass index (BMI) 
and other indices of body fat distribution (13,15-19). In addition, positive correlations have 
been observed between plasma CD36 levels and liver fat in patients with higher liver fat 
content (NAFLD and chronic hepatitis C) (15,20,21) and obesity (17,18). However, very 
little is known about the association of plasma CD36 levels with liver fat and other fat depots 
in the general population. In 1296 healthy individuals free of diabetes and hypertension, a 
positive association of plasma CD36 levels with twoindices of fatty liver has been reported 
(22). In that study, however, no direct measure of liver fat was available; instead, liver fat 
was estimated using two algorithms based on anthropometric (BMI, waist circumference 
[WC]) and biochemical (alanine transaminase [ALT], gamma-glutamyl transferase and 
aspartate aminotransferase, levels of triglycerides and insulin) measures, as well as on the 
presence of metabolic syndrome and type 2 diabetes (22). 
 Non-invasive imaging techniques quantify abdominal fat depots and liver fat content 
more accurately than surrogate anthropometrical measur s including WC, BMI or liver fat 
algorithms (23). Therefore, in the present analysis, we aimed to relate plasma CD36 
concentrations in cross-sectional analyses to magnetic resonance imaging (MRI)-traits of 
liver fat content and body fat distribution in a community-based sample from Northern 
Germany (24). Since the expression of tissue CD36 is much higher in adipose tissue than 
liver (25), we hypothesize that plasma CD36 levels are more strongly related to visceral 
adipose tissue than liver fat content in a general population. 
METHODS 
Study sample 
 The PopGen control cohort is an ongoing prospectiv cohort study among a random 
sample of 1316 individuals living in northern Germany. The design has been described in 
detail previously (26). In brief, at baseline recruitment between 2005 and 2007, the PopGen 
biobank randomly identified 23,000 local residents through population registries in the city of 
Kiel and invited them to participate in the study. A total of 4,267 participants agreed to take 
part, and among them, 747 subjects agreed to partici te in the follow-up study. In addition, 
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the PopGen biobank recruited 569 blood donors at the University Hospital Schleswig-
Holstein in Kiel, and these two groups constituted the final PopGen control cohort (1316 
individuals) (27). The first follow-up examination was conducted between 2010 and 2012, 
and 952 participants agreed to be re-examined at the study center. During this follow-up 
examination, trained study nurses performed a medical examination and drew blood. 
Furthermore, a whole-body MRI was part of this examination cycle, including an assessment 
of liver fat content and body fat distribution. Information on demographics, dietary intake, 
lifestyle factors and medical history was collected via self-administered questionnaires 
(24,26,28).  
For the present analysis, we used data from the first follow-up examination. A total of 
575 participants underwent MRI to assess VAT and SAT, as well as liver fat content. The 
flowchart of the current study design is shown in Supplemental Figure S1. The study 
procedures were approved by the ethical review board f the Medical Faculty of Kiel 
University, Germany. All study participants provided written informed consents. 
Assessment of covariates 
 Information on participants’ characteristics such as age, sex, education, smoking 
status, alcohol consumption, physical activity and medical history was collected using self-
administered questionnaires. Alcohol consumption during the past year was calculated as the 
means of the reported values from a validated food requency questionnaire for German 
populations (29). We quantified physical activity as weekly metabolic equivalent task 
(MET)-hours by summing the reported weekly hours in different activities (walking, cycling, 
sports, gardening, do-it-yourself activities and household tasks (28)) and multiplying them by 
their corresponding MET values averaged for winter and summer (30). Prevalent type 2 
diabetes was determined by self-reported physician-d gnosed type 2 diabetes, antidiabetic 
medication usage, fasting blood glucose levels ≥126 mg/dL or hemoglobin A1c levels ≥6.5% 
at the baseline or at the follow-up visit. In addition, prevalent hypertension was defined as 
self-reported hypertension diagnosed by a physician, usi g hypertension medication, or 
having diastolic blood pressure ≥90 mm Hg or systolic blood pressure ≥140 mm Hg (24,28).  
 Trained study nurses measured WC, body weight and height of participants wearing 
light clothing without shoes (28,31). Study nurses ubtracted 2 kilograms from the measured 
weight to correct for clothing. BMI was calculated as weight (in kilograms) divided by height 
(in meters) squared. WC was measured at the midpoint between the spina iliaca crest and 
lower costal margin (31). Study nurses measured blood pressure three times by 
sphygmomanometry after the participant rested for at least 5 minutes. We calculated the 
arithmetic means of the last two blood pressure measur ments (28).  
Biochemical measurements  
 All participants provided blood samples in a sitting position after overnight fasting. 
Most biosamples were stored at -80 degrees until biomarkers were assayed.  
Standard laboratory parameters (including concentrations of total cholesterol [TC], 
triglycerides [TG], high-density lipoprotein cholest rol [HDL-C], low-density lipoprotein 
cholesterol [LDL-C]) were measured on the day of the examination at the Institute for 
Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Germany (28). ALT was 
assessed by enzymatic colorimetry (Hitachi Modular; Roche Diagnostics), C-reactive protein 
(CRP) levels were determined by immunoturbidimetry, blood glucose levels by enzymatic 
ultraviolet tests (Roche Diagnostics) and HbA1c leve s by HPLC and photometric detection 
(Bio-Rad Laboratories). Plasma CD36 levels were assayed (from samples stored at -80 
degrees) at Aarhus University Hospital by an in-house ELISA assay (13), and the intra-assay 
coefficient of variation was 11%. 
Outcome assessment 
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 We used MRI to quantify the liver fat content and adipose tissue volumes on a 
Magnetom Avanto 1.5-T whole-body imager (Siemens Medical Solutions) (28,32). Study 
nurses performed MRI with participants at the supine position with arms extended over the 
head (32). In-phase and out-of-phase images were acquired during a breath hold by using 
axial T1-weighted gradient echo MRI with a 10.4-ms repetition time, echo time of 4.76 ms 
(in-phase) and 7.14 ms (opposed phase), 10° flip angle, 128 × 80 matrix, and 275 × 440-mm 
field of view (24). Liver fat content was quantified as the relative liver signal intensity (LSI) 
difference of the liver on out-of-phase compared with in-phase images in arbitrary units 
(24,33). We validated the accuracy of LSI to quantify liver fat content using T2-corrected 1H 
single-voxel proton magnetic resonance spectroscopy (MRS) on a 1.5-T whole-body imager 
(Siemens Medical Solutions) as the reference method in a sample of 40 individuals (55% 
men; median age: 55.6 y; median BMI: 27.7 kg/m2) (24). Spearman’s correlation coefficient 
between LSI values and the MRS-determined liver fat content was r = 0.609 (P < 0.001) (24). 
Fatty liver disease (FLD) was determined as log-transformed LSI ≥3.0 according to a cut-off 
value determined by receiver operating characteristic (ROC) analysis using spectroscopic-
determined FLD (liver fat ≥5.56%) as the reference (area under ROC curve: 0.86; 95% 
confidence interval [CI], 0.74-0.98) (24,34). The log-LSI cut-off of ≥3.0 was identified by 
Youden Index, which corresponded to a sensitivity of 0.79 and a specificity of 0.81 (24). 
NAFLD was defined as having FLD in the absence of higher alcohol intake defined as ≤7 
drinks per week for women and ≤14 drinks per week for men (35,36). 
In addition, VAT was determined as the sum of VAT voxels from the top of the liver to 
the femoral heads inside the abdominal muscular wall, and SAT was determined as the sum 
of adipose tissue voxels underneath the skin layer surrounding the abdomen from the top of 
the liver to the femur heads (32). Both VAT and SAT were expressed in decimeters cubed 
(dm3) (28).  
Statistical analysis 
To describe the characteristics of the study participants, we divided the study sample into 
quartiles based on the distribution of plasma CD36 concentrations using sex-specific cut-offs. 
Continuous variables with normal distribution were reported as mean ± standard deviation, 
while continuous variables with skewed distribution were reported as median (Q1, Q3), and 
categorical variables were presented as percentages.  
Spearman partial correlations adjusted for age and sex were estimated between plasma 
CD36 concentrations and LSI, adiposity measures (BMI, WC, VAT, SAT) and blood 
biomarkers, including ALT, glucose, HbA1c, TC, TG, HDL-C, LDL-C, CRP and fetuin-A. 
For participants (n=229) whose CRP values were below the detection limit (0.9 mg/L), half 
of the detection limit (0.45 mg/L) was assigned as their CRP values.  
Cubic spline analysis with four knots at the 5th, 35th, 65th and 95th percentiles (50th 
percentile as referent) was used to assess potential non-linearity of the relations between 
plasma CD36 and FLD as well as NAFLD. When assessing the association between plasma 
CD36 and NAFLD, we excluded participants with self-r ported liver disease (hepatitis A, B, 
C, or D virus infection, hemochromatosis, autoimmune liver disease, or liver cirrhosis, n=18) 
other than FLD. To analyze the associations between plasma CD36 and FLD as well as 
NAFLD, we used multivariable-adjusted logistic regrssion models and calculated odds 
ratios for FLD using the lowest plasma CD36 quartile as the reference category. We adjusted 
for sex, age (continuous), years of education [≤9 years (no level of general education 
completed or secondary general school-leaving certificate), 10 years (intermediate school-
leaving certificate), or ≥11 years (university of applied sciences or university entrance 
qualification)], smoking status [never (smoking period ≤3 months), former (smoking period 
>3 months), or current], physical activity (metabolic equivalent task hours/week; continuous), 
alcohol consumption (continuous) and history of diabetes (yes or no) as potential 
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confounding factors. We additionally adjusted for BMI (model 2) or VAT/SAT (model 3) to 
assess whether the association of CD36 with FLD and NAFLD is independent of these 
adiposity measures. Adjusted means of LSI, BMI, VAT and SAT according to CD36 
quartiles were calculated by analysis of covariance. 
Potential effect modification by sex, median age (< vs. ≥62.3 years), prevalent diabetes 
and prevalent hypertension were tested by including respective multiplicative interaction 
terms in the fully-adjusted regression models. 
Analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, North 
Carolina). All tests were two-sided, and P values <0.05 were considered to be statistically 
significant.  
RESULTS 
 The median age of this sample was 62.3 (range: 25.1-82.8) years at the first follow-up 
examination. Characteristics of the study sample according to the sex-specific quartiles of 
plasma CD36 levels are shown in Table 1. In unadjusted statistical models, compared to 
people with lower plasma CD36 levels, individuals with higher CD36 levels had higher mean 
values for different adiposity measures (BMI, WC, SAT, VAT), diastolic and systolic blood 
pressure, ALT, a higher prevalence of FLD and NAFLD and lower education levels.  
 Plasma CD36 levels were positively correlated with BMI, WC, SAT, VAT, ALT, 
total cholesterol and TG but not with LSI (r =0.03; P =0.44), HDL-C (r =-0.01; P =0.85), or 
LDL-C (r =0.07; P =0.09) in age- and sex-adjusted analyses (Supplemental Table S1). 
In multivariable-adjusted least square-means analyses u ing the first CD36-quartile as 
referent, participants in the second, third and fourth CD36 quartile had significantly higher 
levels of BMI, SAT and VAT with a graded increase across quartiles (all P-trend <0.05; 
Table 2), however, such a graded association was not observed for LSI (P-trend >0.10). In 
addition, BMI, SAT and VAT explained 8%, 17% and 13% of the variance in plasma CD36 
concentrations, respectively; whereas LSI explained 1% of the variance of plasma CD36.  
The association of plasma CD36 levels with FLD and NAFLD is shown in Supplemental 
Table S2. Restricted cubic spline analysis did not suggest a nonlinear association of plasma 
CD36 levels with FLD and NAFLD (data not shown). After adjusting for age, sex, education 
levels, smoking status, alcohol intake, physical activity and prevalent diabetes, higher CD36 
concentrations conferred slightly higher odds for FLD (highest vs. lowest quartile, odds ratio 
[OR]: 1.13; 95% CI, 0.69, 1.87) and NAFLD (highest v . lowest quartile, OR: 1.28; 95% CI: 
0.74, 2.22), but the respective odds ratios were not statistically significant. The risk estimate 
of CD36 for liver fat was further attenuated towards the null after adjustment for BMI 
(highest vs. lowest quartile, OR for FLD: 0.98; 95% CI: 0.58, 1.64; OR for NAFLD: 1.09; 
95% CI: 0.62, 1.92) or adjustment for VAT/SAT (highest vs. lowest quartile, OR for FLD: 
1.02; 95% CI: 0.61, 1.70; OR for NAFLD: 1.15; 95% CI: 0.66, 2.01; Supplemental Table 
S2).  
We also compared mean CD36 levels in individuals with NAFLD and normal ALT 
concentrations (≤33 IU/L in men and ≤25 IU/L in women; n=113) to CD36 levels of 
participants with NAFLD and elevated ALT concentrations (n=70). CD36 levels were 
statistically significantly higher in individuals with NAFLD and ALT (1.58 ± 0.82 units vs.  
1.21 ± 0.72 units; P=0.002).  
We found no evidence for effect modification by sex, age, prevalent diabetes and 
prevalent hypertension (all P-interaction >0.05).All supplemental materials were stored at the 
public data repository (37). 
DISCUSSION 
Principal observations  
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In this cross-sectional analysis in a population-based sample, we observed statistically 
significant correlations between plasma CD36 levels and different markers of general and 
abdominal adiposity, including BMI, WC, VAT and SAT. By contrast, no association of 
plasma CD36 concentrations with liver fat content, FLD and NAFLD was observed.  
In the context of the published literature 
With the present analyses on MRI-derived traits of liver fat, SAT and VAT in addition to 
BMI and WC, we expand on prior studies that have repo t d positive correlations of plasma 
CD36 with adiposity markers (mainly BMI and WC) (13, 5,17-19,22) and liver fat content 
(15,17,18,20-22) in other European samples, mainly in samples with defined disease 
conditions such as liver disease or obesity. Several prior studies have consistently observed a 
positive correlation between plasma CD36 levels and BMI (13,17,18,22). However, since 
BMI does not differentiate between body fat and muscle weight and since visceral fat may 
play a greater role in contributing to metabolic diseases than subcutaneous fat (38,39), more 
detailed analyses regarding the association of CD36 levels with different fat depots were 
warranted. In 111 NAFLD patients and 33 healthy controls, an inverse correlation between 
plasma CD36 levels and dual-energy X-ray absorbiometry VAT (r=-0.21; P <0.05), but no 
correlation with SAT, were reported (15). Other indicators of body composition such as WC, 
fat mass, central fat mass and truncal fat mass have also shown to be positively correlated 
with plasma CD36 levels in women with polycystic ovary syndrome (19), in obese children 
(18) and in morbidly obese individuals (17) receiving lifestyle intervention programs and 
gastric bypass surgeries, respectively, for weight loss.  
In our comprehensive analyses in a community-based sample, we related plasma CD36 
levels to a broad panel of adiposity measures, and observed a consistent and positive 
association of CD36 levels with VAT, SAT and BMI in different multivariable-adjusted 
statistical models. Furthermore, higher plasma CD36 levels have been related to greater liver 
fat content in clinical samples (e. g. in patients with NAFLD or chronic hepatitis C) 
(15,20,21)), in individuals with obesity (17,18), and also in general population samples (22). 
In contrast to these former studies, plasma CD36 levels were unrelated to liver fat content in 
our analyses in a community-dwelling sample, free of apparent liver disease. One potential 
explanation for the lack of association in our study is that the association of CD36 with liver 
fat might be much more pronounced (or only apparent) in clinical settings or in obese 
individuals, but not in relatively healthy individuals from the community. Indeed, clinical 
study groups with significantly elevated plasma CD36 as previously reported had liver fat 
content of 20-30% (15,20,21), while our sample included many normal weight participants 
free of liver disease. 
Furthermore, in our sample, CD36 levels were higher in individuals with NAFLD and 
elevated ALT concentrations as compared to individuals with NAFLD and normal ALT 
concentrations. Thus, CD36 concentrations might be more closely related to more severe 
liver cell damage (indicated by increased ALT levels) than to increased fat deposition in the 
liver.  
In addition, differences in the definition of NAFLD and in the assessment of liver fat 
content have to be considered when comparing the results across studies (15,20-22). Previous 
studies among clinical samples used MRS (intrahepatic lipid content >5%) or liver biopsy in 
the absence of excessive alcohol intake to define NAFLD (15,20,21), while the current study 
defined NALFD using MRI-measured LSI (log LSI ≥3.0) in the absence of high alcohol 
intake (≤7 drinks/week for women and ≤14 drinks/week for men). In terms of liver fat 
content, a prior study conducted in a general population sample did not directly measure or 
visualize liver fat content, but estimated liver fat b sed on algorithms including BMI, WC, 
triglycerides, liver transaminases, fasting insulin and presence of diabetes and metabolic 
syndrome (22). Of note, most variables included in the algorithm to predict liver fat in the 
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previous study (22), such as BMI, WC, triglycerides and ALT, were also significantly 
correlated with plasma CD36 in our sample (Supplemental Table S1). By contrast, our study 
took advantage of MRI techniques to quantify liver fat content. However, liver fat content 
might not necessarily reflect NAFLD severity. A previous study suggested that liver fat 
content decreases in some patients with NAFLD progressing to cirrhosis (40). Long term 
prospective studies assessing fatty liver disease sev rity including fibrosis are warranted to 
better understand the association between circulating CD36 concentrations, liver fat (as 
assessed by MRI), biochemical markers of liver functio  and damage and NAFLD. 
Potential mechanisms for the observed associations  
Several experimental data support the observed associ tion between plasma CD36 and 
adipose tissue traits. CD36 acts as a membrane fatty acid transporter (9) and has been shown 
to bind long-chain fatty acids (LCFA) and facilitate LCFA uptake across the plasma 
membrane in adipose tissue (41). In line with this biological function, an increased 
expression of CD36 has been observed on both, mRNA and plasma membrane level in VAT 
and SAT of obese individuals (42), and genetic variants in the CD36 gene have been linked 
to lipid metabolism and obesity (10-12). Further, CD36 expression in the liver and plasma 
CD36 are correlated (15,20,21). Even though the mechanism of CD36 release into the 
circulation is currently unknown, it has been hypothesized that metabolic abnormalities such 
as inflammation in abdominal obesity could promote plasma CD36 release into the 
circulation (6).  
Strengths and limitations 
The strengths of the current study include its large sample size, the community-based design 
and the comprehensive clinical examination of the sudy participants, including assessment of 
different adipose tissues (including assessments of liver fat content on a continuous scale; a 
method that has been validated against MRS (24)) using MRI and detailed assessment of 
potentially confounding factors. Thus, we were able to adjust for a variety of lifestyle factors 
in our statistical analyses. The following limitations merit consideration. First, since this was 
a cross-sectional analysis, the causality and temporality of the relation of plasma CD36 levels 
with the different outcome measures could not be det rmined. Moreover, NAFLD was not 
diagnosed by liver biopsy in the current study, since this is not feasible and not ethically 
justifiable in a community-based setting. Therefore, w  could not differentiate between 
different stages of NAFLD and their respective relations with plasma CD36 levels. Further 
studies are warranted that compare the accuracy of MRI-determined liver fat content to 
proton density fat-fraction, which is less confounded by biological, physical and technical 
factors (43) and has shown to accurately classify dif erent grades of hepatic steatosis in 
patients with NAFLD (44,45). Additionally, the current study was based on a community-
based sample from Northern Germany. Thus, our observations may not be generalizable to 
other populations.  
CONCLUSIONS 
 In conclusion, higher plasma CD36 concentrations were statistically significantly 
associated with greater measures of general and abdominal adiposity, including higher values 
of MRI-determined SAT and VAT. However, CD36 levels were not related to MRI-
determined liver fat content in our sample from the general population. These observations 
are consistent with the concept that plasma CD36 levels are relevant correlates of adipose 
tissue and provide initial evidence that plasma CD36 might be more closely related to SAT 
and VAT than liver fat content in the general population, a premise that needs further 
investigations. Individuals with NAFLD and elevated ALT had higher plasma CD36 levels 
than individuals with NAFLD and normal ATL levels. Thus, plasma CD36 may reflect more 
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advanced stages of NAFLD. Further population-based stu ies, e.g. with repeated 
measurements of plasma CD36 are warranted to describ  trajectories of CD36 levels over 
time and their prospective association with metabolic and adiposity traits. Finally, studies on 
environmental, lifestyle and genetic factors associated with circulating CD36 are warranted.   
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Table 1. Characteristics of the study sample (n=575), stratified by sex-specific quartiles of 
plasma CD36.  
 Quartiles of CD36 
 Q1 (n=143) Q2 (n=143) Q3 (n=145) Q4 (n=144) 
Median CD36, arbitrary unit (Q25, Q75) for 
men 
0.57 (0.48, 0.70) 1.02 (0.89, 1.13) 1.53 (1.38, 1.64) 2.47 (1.99, 3.02) 
Median CD36, arbitrary unit (Q25, Q75) for 
women 
0.54 (0.43, 0.63) 0.89 (0.81, 1.02) 1.23 (1.14, 1.40) 1.95 (1.81, 2.34) 
Men, (%) 57.3 58.0 56.6 57.6 
Age, y 62.4 (53.7, 70.9) 64.0 (54.7, 72.4) 61.7 (55.5, 69.4) 61.3 (53.5, 69.0) 
Body mass index, (kg/m2)   26.4 ± 4.0 26.8 ± 4.4 27.1 ± 4.1 27.9 ± 4.6 
Waist circumference for men, cm 97.3 ± 9.9 99.6 ± 10.3 99.9 ± 10.0 101.2 ± 11.2 
Waist circumference for women, cm  88.1 ± 12.6 90.0 ± 12.6 89.9 ± 13.3 93.5 ± 14.1 
Systolic blood pressure, mmHg  138.3 ± 17.2 139.5 ± 18.5 140.8 ± 19.2 138.9 ± 18.8 
Prevalent diabetes, % 8.4 13.3 8.28 13.2 
Current smokers, % 11.9 11.9 6.90 9.72 
Physical activity, MET-hr/wk  97.5 (56.8, 141.7) 92.8 (58.0, 123.5) 84.5 (61.8, 124.8) 88.0 (56.3, 128.8) 
High education, % 39.2 34.3 34.5 32.6 
Alcohol consumption, g/d 9.03 (2.89, 15.9) 10.1 (2.62, 21.2) 9.15 (3.68, 19.5) 9.93 (4.91, 17.0) 
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SAT, dm3 5.40 (4.36, 7.53) 6.20 (4.46, 8.11) 6.12 (4.74, 8.18) 6.84 (5.28, 9.38) 
VAT, dm3 3.09 (2.12, 4.64) 4.10 (2.56, 5.44) 3.78 (2.41, 4.96) 4.21 (2.89, 5.62) 
ALT, IU/L 21.0 (16.0, 27.0) 22.0 (17.0, 28.0) 23.0 (17.0, 31.0) 25.0 (18.0, 32.0) 
Liver signal intensity 2.89 ± 0.41 2.93 ± 0.39 2.98 ± 0.43 2.95 ± 0.54 
Fatty liver disease, % 37.8 37.8 42.8 43.8 
Non-alcoholic fatty liver disease, % 32.6 32.1 37.1 37.7 
Data are reported as mean ± standard deviation for continuous normally distributed variables (body mass index, 
waist circumference, systolic blood pressure and liver signal intensity) and as median (Q25, Q75) for continuous 
skewed distributed variables (CD36, age, physical ativity, alcohol consumption, SAT, VAT and ALT) and as 
percentage for categorical variables. Abbreviations: CD36, cluster of differentiation 36; MET, metabolic 
equivalent; SAT, subcutaneous abdominal adipose tisue; VAT, visceral abdominal adipose tissue; ALT, alanine 
aminotransferase. 
Table 2. Multivariable-adjusted means (95% CI) of different MRI-derived adiposity traits 
and measures of liver fat, stratified by sex-specific quartiles of plasma CD36 (n=575). 
 Multivariable-adjusted means (95% CI) by quartiles of CD36 
P for trenda  Q1 (n=143) Q2 (n=147) Q3 (n=140) Q4 (n=146) 
Liver signal intensity      
   Model 1b 2.90 (2.83, 2.98) 2.93 (2.86, 3.00) 2.99 (2.91, 3.06) 2.96 (2.89, 3.03) 0.38 
   Model 2c 3.05 (2.96, 3.14) 3.04 (2.95, 3.13) 3.11 (3.02, 3.20) 3.07 (2.98, 3.15) 0.36 
   Mean difference (95% CI), Model 2 0 (Reference) -0.01 (-0.12, 0.11) 0.06 (-0.05, 0.18) 0.02 (-0.10, 0.14)  
BMI, kg/m2      
   Model 1b 26.4 (25.7, 27.1) 26.8 (26.1, 27.5) 27.1 (26.4, 27.8) 27.9 (27.2, 28.6) 0.022 
   Model 2c 27.8 (26.9, 28.6) 27.9 (27.1, 28.8) 28.2 (27.3, 29.1) 28.9 (28.0, 29.7) 0.013 
   Mean difference (95% CI), Model 2 0 (Reference) 0.16 (-0.99, 1.31) 0.47 (-0.67, 1.62) 1.13 (-0.03, 2.28)  
VAT, dm3      
   Model 1b 3.38 (3.08, 3.68) 4.07 (3.77, 4.36) 3.86 (3.56, 4.16) 4.22 (3.93, 4.52) <0.001 
   Model 2c 4.13 (3.77, 4.48) 4.65 (4.31, 5.00) 4.50 (4.14, 4.86) 4.71 (4.36, 5.06) <0.001 
   Mean difference (95% CI), Model 2 0 (Reference) 0.53 (0.05, 1.00) 0.38 (-0.10, 0.86) 0.59 (0.11, 1.07)  
  SAT, dm3   
   Model 1b 6.40 (5.85, 6.94) 6.99 (6.46, 7.53) 7.10 (6.55, 7.65) 7.87 (7.33, 8.41) 0.002 
   Model 2c 7.61 (6.96, 8.27) 7.99 (7.36, 8.63) 8.21 (7.54, 8.87) 8.74 (8.10, 9.38) <0.001 
   Mean difference (95% CI), Model 2 0 (Reference) 0.38 (-0.49, 1.25) 0.59 (-0.29, 1.47) 1.13 (0.25, 2.01)  
aLinear trend was tested per standard deviation increment of plasma CD36 levels. bModel 1: Adjusted for age 
and sex. cModel 2: Model 1 additionally adjusted for education levels (≤9, 10 or ≥11 years), smoking status 
(never, former or current smoker), physical activity (continuous), prevalent diabetes (yes or no) and alcohol 
intake (continuous). Abbreviations: BMI, body mass index; CD36, cluster of differentiation 36; CI, confidence 
interval; VAT, visceral abdominal adipose tissue; SAT, subcutaneous abdominal adipose tissue; Q, quartile.  A
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